Early Stage Researcher – Project 12 - European Training Network
We are looking for an Early Stage Researcher to join OncoMark (www.oncomark.com). Our offices and laboratory are based at NovaUCD, which is a Technology Transfer and Innovation Centre at University College Dublin, Ireland (www.ucd.ie/nova). The successful candidate will be employed by OncoMark. OncoMark is currently involved in a number of EU funded projects, including a new pan-European academic/private sector research training network project called MEL-PLEX –Identifying and validating a panel of master transcriptional regulators in advanced melanoma, using a systems transcriptomics and histology approach (Project 12).
Specific melanoma cohort data has been analysed and key network targets that regulate transcription have been identified. The candidate will validate these potential targets using tissue analysis techniques (WB, IHC) and process the data using advanced digital image analysis, statistical analysis and data driven systems modelling.
Eligibility and Candidate requirements:
IMPORTANT: At the time of recruitment, the candidate must not have resided or carried out their main activity (work, studies, etc.) in the country of their recruiting organisation for more than 12 months in the 3 years immediately prior to start of the project. Short stays such as holidays and/or compulsory national service are not taken into account. Candidates can be of any nationality, but are required to undertake transnational mobility.
Candidates should ideally possess a Master’s degree in a relevant academic field.
Experience/techniques (desirable but not essential);
- Cancer Research (particularly melanoma)/Immunohistochemical assays/Molecular biological techniques (western blotting/histology/cell culture)
- Good Computer/Bioinformatic/Biostatistics skills, an advantage
Ideal candidates should be motivated and should possess excellent communication skills, as well as strong organizational skills with a high level of attention to detail. In addition, applicants should have the ability to work independently and as part of a team and have a willingness to travel abroad to promote the company and interact with collaborators.
For more information about this role, please email firstname.lastname@example.org
- A full CV, a covering letter including a description of previous research experiences and contact details or recommendation letters of two 2 referees;
- Submit the documentation to email@example.com by Tuesday 5th December 2017 at 5 pm (GMT). Please note that applications failing to contain the requested documentation WILL NOT be considered in this competition.
- Salary will be competitive.
- Contract: 6-month contract commencing 02/01/2018 (flexibility in commencement date if required)
Overview of the European Training Network programme:
The programme is funded through the Horizon 2020 Marie Skłodowska Curie Actions and it involves 15 projects. To obtain more details please visit:
In the absence of personalised and optimised treatment options, great numbers of cancer patients suffer from inefficient therapies. Malignant melanoma exemplifies a largely chemotherapy-resistant, highly heterogeneous and aggressive cancer. Novel treatment options for personalised, patient-tailored melanoma therapies can now be explored or developed through newly emerging and innovative research disciplines that go significantly beyond the current state-of-the-art, such as translational cancer systems biology and cancer systems medicine.
The main objectives are to (i) achieve an unmatched depth of molecular and mechanistic disease understanding, (ii) exploit this knowledge to develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iii) provide superior and clinically relevant tools and biomarker signatures for personalising and optimising melanoma therapy.
All projects comprise experimental approaches as well as advanced data analysis or systems modelling approaches.
OncoMark Ltd is an Irish private company centred on the development and clinical application of cancer biomarkers. OncoMark was spun out of UCD and the overall company strategy is to develop and validate protein biomarker panels, using advanced histology technologies, specifically to develop predictive tests for patient outcome and stratification with cancer treatment. The company conducts in house research and development in this arena and has developed key expertise in TMA construction, digital slide scanning, automated image analysis and statistics. The company has also developed a proprietary in-house image analysis toolkit for assessment of IHC based markers at the subcellular compartmental level.